BioNTech's Q3 revenue falls on lower COVID-19 vaccine demand

Overview

• Germany biopharma firm's Q3 revenue declined yr/yr on lower COVID-19 vaccine demand

• Adjusted diluted EPS and net profit for Q3 fell from prior year

• Company raised full-year 2026 revenue guidance midpoint, citing Q3 performance

Outlook

• BioNTech raises full-year 2026 revenue guidance midpoint to €1.7–1.9 bln

• Company maintains guidance for 2026 adjusted R&D expenses at €2.0–2.3 bln

• Company maintains guidance for 2026 adjusted SG&A expenses at €700–800 mln

Result Drivers

• COVID-19 VACCINE DEMAND - Co said expected lower market demand for COVID-19 vaccines drove revenue decline

• ONCOLOGY INVESTMENT - Higher R&D expenses mainly due to increased spending on late-stage immuno-oncology and antibody-drug conjugate programs

• PIPELINE PRIORITIZATION - Impairment and restructuring costs from pipeline prioritization affected operating results

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", 8 "hold" and no "sell" or "strong sell"

Reuters Recommended Reads

• Nov 2 - Switzerland's CRISPR Therapeutics Q3 CASGEVY revenue jumps 30% sequentially

• Nov 2 - Ireland's Jazz Pharmaceuticals Q3 revenue beats; 2026 outlook lifted

• Nov 3 - Lonza to buy five US sites from Merck KGaA

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)